Monoclonal antibodies are single cell clones of antibodies, a biochemical tool that allows scientists to create antibodies that combine the specificity of specific substances. There are many reasons for the medical community to support the use of monoclonal antibodies in cancer treatment. There are a few clinical trials.

The global Cancer Monoclonal Antibody Partnering Terms and Agreements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

North American market for Cancer Monoclonal Antibody Partnering Terms and Agreements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Cancer Monoclonal Antibody Partnering Terms and Agreements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global market for Cancer Monoclonal Antibody Partnering Terms and Agreements in Pharmaceutical Industry is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global companies of Cancer Monoclonal Antibody Partnering Terms and Agreements include 3SBio, 4D Pharma, Abbvie, Abzena, Adaptive Biotechnologies, Aeglea BioTherapeutics, Agenus Bio, Ascension and Ascentage Pharma, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Cancer Monoclonal Antibody Partnering Terms and Agreements, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Monoclonal Antibody Partnering Terms and Agreements.

Report Scope

The Cancer Monoclonal Antibody Partnering Terms and Agreements market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cancer Monoclonal Antibody Partnering Terms and Agreements market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Cancer Monoclonal Antibody Partnering Terms and Agreements companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Cancer Monoclonal Antibody Partnering Terms and Agreements Market Report

Report Metric	Details
Report Name	Cancer Monoclonal Antibody Partnering Terms and Agreements Market
Segment by Type	Asset Purchase Collaborative R&D Joint Venture Licensing Other
Segment by Application	Pharmaceutical Industry Biotechnology Medical Care Education and Research Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	3SBio, 4D Pharma, Abbvie, Abzena, Adaptive Biotechnologies, Aeglea BioTherapeutics, Agenus Bio, Ascension, Ascentage Pharma, Aslan Pharma, Telix Pharmaceuticals, Basilea Pharmaceutica, Bavarian Nordic, Baxalta, Bayer, Cantargia, Apollomics, Chiome Bioscience, Clovis Oncology
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cancer Monoclonal Antibody Partnering Terms and Agreements companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Cancer Monoclonal Antibody Partnering Terms and Agreements Market report?

Ans: The main players in the Cancer Monoclonal Antibody Partnering Terms and Agreements Market are 3SBio, 4D Pharma, Abbvie, Abzena, Adaptive Biotechnologies, Aeglea BioTherapeutics, Agenus Bio, Ascension, Ascentage Pharma, Aslan Pharma, Telix Pharmaceuticals, Basilea Pharmaceutica, Bavarian Nordic, Baxalta, Bayer, Cantargia, Apollomics, Chiome Bioscience, Clovis Oncology

What are the Application segmentation covered in the Cancer Monoclonal Antibody Partnering Terms and Agreements Market report?

Ans: The Applications covered in the Cancer Monoclonal Antibody Partnering Terms and Agreements Market report are Pharmaceutical Industry, Biotechnology, Medical Care, Education and Research, Other

What are the Type segmentation covered in the Cancer Monoclonal Antibody Partnering Terms and Agreements Market report?

Ans: The Types covered in the Cancer Monoclonal Antibody Partnering Terms and Agreements Market report are Asset Purchase, Collaborative R&D, Joint Venture, Licensing, Other

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Asset Purchase

1.2.3 Collaborative R&D

1.2.4 Joint Venture

1.2.5 Licensing

1.2.6 Other

1.3 Market by Application

1.3.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Pharmaceutical Industry

1.3.3 Biotechnology

1.3.4 Medical Care

1.3.5 Education and Research

1.3.6 Other

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Perspective (2019-2030)

2.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Growth Trends by Region

2.2.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Historic Market Size by Region (2019-2024)

2.2.3 Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Region (2025-2030)

2.3 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Dynamics

2.3.1 Cancer Monoclonal Antibody Partnering Terms and Agreements Industry Trends

2.3.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Drivers

2.3.3 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Challenges

2.3.4 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Cancer Monoclonal Antibody Partnering Terms and Agreements Players by Revenue

3.1.1 Global Top Cancer Monoclonal Antibody Partnering Terms and Agreements Players by Revenue (2019-2024)

3.1.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Players (2019-2024)

3.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue

3.4 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Concentration Ratio

3.4.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in 2023

3.5 Cancer Monoclonal Antibody Partnering Terms and Agreements Key Players Head office and Area Served

3.6 Key Players Cancer Monoclonal Antibody Partnering Terms and Agreements Product Solution and Service

3.7 Date of Enter into Cancer Monoclonal Antibody Partnering Terms and Agreements Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Cancer Monoclonal Antibody Partnering Terms and Agreements Breakdown Data by Type

4.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Historic Market Size by Type (2019-2024)

4.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Type (2025-2030)

5 Cancer Monoclonal Antibody Partnering Terms and Agreements Breakdown Data by Application

5.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Historic Market Size by Application (2019-2024)

5.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2019-2030)

6.2 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2019-2024)

6.4 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2019-2030)

7.2 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2019-2024)

7.4 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2019-2030)

8.2 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region (2019-2024)

8.4 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2019-2030)

9.2 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2019-2024)

9.4 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2019-2030)

10.2 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2019-2024)

10.4 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 3SBio

11.1.1 3SBio Company Detail

11.1.2 3SBio Business Overview

11.1.3 3SBio Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.1.4 3SBio Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.1.5 3SBio Recent Development

11.2 4D Pharma

11.2.1 4D Pharma Company Detail

11.2.2 4D Pharma Business Overview

11.2.3 4D Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.2.4 4D Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.2.5 4D Pharma Recent Development

11.3 Abbvie

11.3.1 Abbvie Company Detail

11.3.2 Abbvie Business Overview

11.3.3 Abbvie Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.3.4 Abbvie Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.3.5 Abbvie Recent Development

11.4 Abzena

11.4.1 Abzena Company Detail

11.4.2 Abzena Business Overview

11.4.3 Abzena Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.4.4 Abzena Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.4.5 Abzena Recent Development

11.5 Adaptive Biotechnologies

11.5.1 Adaptive Biotechnologies Company Detail

11.5.2 Adaptive Biotechnologies Business Overview

11.5.3 Adaptive Biotechnologies Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.5.4 Adaptive Biotechnologies Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.5.5 Adaptive Biotechnologies Recent Development

11.6 Aeglea BioTherapeutics

11.6.1 Aeglea BioTherapeutics Company Detail

11.6.2 Aeglea BioTherapeutics Business Overview

11.6.3 Aeglea BioTherapeutics Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.6.4 Aeglea BioTherapeutics Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.6.5 Aeglea BioTherapeutics Recent Development

11.7 Agenus Bio

11.7.1 Agenus Bio Company Detail

11.7.2 Agenus Bio Business Overview

11.7.3 Agenus Bio Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.7.4 Agenus Bio Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.7.5 Agenus Bio Recent Development

11.8 Ascension

11.8.1 Ascension Company Detail

11.8.2 Ascension Business Overview

11.8.3 Ascension Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.8.4 Ascension Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.8.5 Ascension Recent Development

11.9 Ascentage Pharma

11.9.1 Ascentage Pharma Company Detail

11.9.2 Ascentage Pharma Business Overview

11.9.3 Ascentage Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.9.4 Ascentage Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.9.5 Ascentage Pharma Recent Development

11.10 Aslan Pharma

11.10.1 Aslan Pharma Company Detail

11.10.2 Aslan Pharma Business Overview

11.10.3 Aslan Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.10.4 Aslan Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.10.5 Aslan Pharma Recent Development

11.11 Telix Pharmaceuticals

11.11.1 Telix Pharmaceuticals Company Detail

11.11.2 Telix Pharmaceuticals Business Overview

11.11.3 Telix Pharmaceuticals Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.11.4 Telix Pharmaceuticals Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.11.5 Telix Pharmaceuticals Recent Development

11.12 Basilea Pharmaceutica

11.12.1 Basilea Pharmaceutica Company Detail

11.12.2 Basilea Pharmaceutica Business Overview

11.12.3 Basilea Pharmaceutica Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.12.4 Basilea Pharmaceutica Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.12.5 Basilea Pharmaceutica Recent Development

11.13 Bavarian Nordic

11.13.1 Bavarian Nordic Company Detail

11.13.2 Bavarian Nordic Business Overview

11.13.3 Bavarian Nordic Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.13.4 Bavarian Nordic Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.13.5 Bavarian Nordic Recent Development

11.14 Baxalta

11.14.1 Baxalta Company Detail

11.14.2 Baxalta Business Overview

11.14.3 Baxalta Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.14.4 Baxalta Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.14.5 Baxalta Recent Development

11.15 Bayer

11.15.1 Bayer Company Detail

11.15.2 Bayer Business Overview

11.15.3 Bayer Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.15.4 Bayer Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.15.5 Bayer Recent Development

11.16 Cantargia

11.16.1 Cantargia Company Detail

11.16.2 Cantargia Business Overview

11.16.3 Cantargia Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.16.4 Cantargia Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.16.5 Cantargia Recent Development

11.17 Apollomics

11.17.1 Apollomics Company Detail

11.17.2 Apollomics Business Overview

11.17.3 Apollomics Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.17.4 Apollomics Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.17.5 Apollomics Recent Development

11.18 Chiome Bioscience

11.18.1 Chiome Bioscience Company Detail

11.18.2 Chiome Bioscience Business Overview

11.18.3 Chiome Bioscience Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.18.4 Chiome Bioscience Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.18.5 Chiome Bioscience Recent Development

11.19 Clovis Oncology

11.19.1 Clovis Oncology Company Detail

11.19.2 Clovis Oncology Business Overview

11.19.3 Clovis Oncology Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.19.4 Clovis Oncology Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.19.5 Clovis Oncology Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Adaptive Biotechnologies

Aeglea BioTherapeutics

Telix Pharmaceuticals

Basilea Pharmaceutica

List of Tables

Table 1. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Asset Purchase

Table 3. Key Players of Collaborative R&D

Table 4. Key Players of Joint Venture

Table 5. Key Players of Licensing

Table 6. Key Players of Other

Table 7. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 8. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 9. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region (2019-2024) & (US$ Million)

Table 10. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Region (2019-2024)

Table 11. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 12. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Region (2025-2030)

Table 13. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Trends

Table 14. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Drivers

Table 15. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Challenges

Table 16. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Restraints

Table 17. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue by Players (2019-2024) & (US$ Million)

Table 18. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Players (2019-2024)

Table 19. Global Top Cancer Monoclonal Antibody Partnering Terms and Agreements Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements as of 2023)

Table 20. Ranking of Global Top Cancer Monoclonal Antibody Partnering Terms and Agreements Companies by Revenue (US$ Million) in 2023

Table 21. Global 5 Largest Players Market Share by Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (CR5 and HHI) & (2019-2024)

Table 22. Key Players Headquarters and Area Served

Table 23. Key Players Cancer Monoclonal Antibody Partnering Terms and Agreements Product Solution and Service

Table 24. Date of Enter into Cancer Monoclonal Antibody Partnering Terms and Agreements Market

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2019-2024) & (US$ Million)

Table 27. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Type (2019-2024)

Table 28. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 29. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Type (2025-2030)

Table 30. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2019-2024) & (US$ Million)

Table 31. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Application (2019-2024)

Table 32. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 33. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Application (2025-2030)

Table 34. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 35. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2019-2024) & (US$ Million)

Table 36. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2025-2030) & (US$ Million)

Table 37. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 38. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2019-2024) & (US$ Million)

Table 39. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2025-2030) & (US$ Million)

Table 40. Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 41. Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region (2019-2024) & (US$ Million)

Table 42. Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region (2025-2030) & (US$ Million)

Table 43. Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2019-2024) & (US$ Million)

Table 45. Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2025-2030) & (US$ Million)

Table 46. Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 47. Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2019-2024) & (US$ Million)

Table 48. Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2025-2030) & (US$ Million)

Table 49. 3SBio Company Detail

Table 50. 3SBio Business Overview

Table 51. 3SBio Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 52. 3SBio Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 53. 3SBio Recent Development

Table 54. 4D Pharma Company Detail

Table 55. 4D Pharma Business Overview

Table 56. 4D Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 57. 4D Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 58. 4D Pharma Recent Development

Table 59. Abbvie Company Detail

Table 60. Abbvie Business Overview

Table 61. Abbvie Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 62. Abbvie Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 63. Abbvie Recent Development

Table 64. Abzena Company Detail

Table 65. Abzena Business Overview

Table 66. Abzena Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 67. Abzena Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 68. Abzena Recent Development

Table 69. Adaptive Biotechnologies Company Detail

Table 70. Adaptive Biotechnologies Business Overview

Table 71. Adaptive Biotechnologies Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 72. Adaptive Biotechnologies Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 73. Adaptive Biotechnologies Recent Development

Table 74. Aeglea BioTherapeutics Company Detail

Table 75. Aeglea BioTherapeutics Business Overview

Table 76. Aeglea BioTherapeutics Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 77. Aeglea BioTherapeutics Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 78. Aeglea BioTherapeutics Recent Development

Table 79. Agenus Bio Company Detail

Table 80. Agenus Bio Business Overview

Table 81. Agenus Bio Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 82. Agenus Bio Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 83. Agenus Bio Recent Development

Table 84. Ascension Company Detail

Table 85. Ascension Business Overview

Table 86. Ascension Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 87. Ascension Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 88. Ascension Recent Development

Table 89. Ascentage Pharma Company Detail

Table 90. Ascentage Pharma Business Overview

Table 91. Ascentage Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 92. Ascentage Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 93. Ascentage Pharma Recent Development

Table 94. Aslan Pharma Company Detail

Table 95. Aslan Pharma Business Overview

Table 96. Aslan Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 97. Aslan Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 98. Aslan Pharma Recent Development

Table 99. Telix Pharmaceuticals Company Detail

Table 100. Telix Pharmaceuticals Business Overview

Table 101. Telix Pharmaceuticals Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 102. Telix Pharmaceuticals Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 103. Telix Pharmaceuticals Recent Development

Table 104. Basilea Pharmaceutica Company Detail

Table 105. Basilea Pharmaceutica Business Overview

Table 106. Basilea Pharmaceutica Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 107. Basilea Pharmaceutica Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 108. Basilea Pharmaceutica Recent Development

Table 109. Bavarian Nordic Company Detail

Table 110. Bavarian Nordic Business Overview

Table 111. Bavarian Nordic Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 112. Bavarian Nordic Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 113. Bavarian Nordic Recent Development

Table 114. Baxalta Company Detail

Table 115. Baxalta Business Overview

Table 116. Baxalta Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 117. Baxalta Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 118. Baxalta Recent Development

Table 119. Bayer Company Detail

Table 120. Bayer Business Overview

Table 121. Bayer Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 122. Bayer Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 123. Bayer Recent Development

Table 124. Cantargia Company Detail

Table 125. Cantargia Business Overview

Table 126. Cantargia Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 127. Cantargia Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 128. Cantargia Recent Development

Table 129. Apollomics Company Detail

Table 130. Apollomics Business Overview

Table 131. Apollomics Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 132. Apollomics Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 133. Apollomics Recent Development

Table 134. Chiome Bioscience Company Detail

Table 135. Chiome Bioscience Business Overview

Table 136. Chiome Bioscience Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 137. Chiome Bioscience Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 138. Chiome Bioscience Recent Development

Table 139. Clovis Oncology Company Detail

Table 140. Clovis Oncology Business Overview

Table 141. Clovis Oncology Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 142. Clovis Oncology Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 143. Clovis Oncology Recent Development

Table 144. Research Programs/Design for This Report

Table 145. Key Data Information from Secondary Sources

Table 146. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Type: 2023 VS 2030

Figure 3. Asset Purchase Features

Figure 4. Collaborative R&D Features

Figure 5. Joint Venture Features

Figure 6. Licensing Features

Figure 7. Other Features

Figure 8. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 9. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application: 2023 VS 2030

Figure 10. Pharmaceutical Industry Case Studies

Figure 11. Biotechnology Case Studies

Figure 12. Medical Care Case Studies

Figure 13. Education and Research Case Studies

Figure 14. Other Case Studies

Figure 15. Cancer Monoclonal Antibody Partnering Terms and Agreements Report Years Considered

Figure 16. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 17. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 18. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Region: 2023 VS 2030

Figure 19. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Players in 2023

Figure 20. Global Top Cancer Monoclonal Antibody Partnering Terms and Agreements Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements as of 2023)

Figure 21. The Top 10 and 5 Players Market Share by Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in 2023

Figure 22. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Country (2019-2030)

Figure 24. United States Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. Canada Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Country (2019-2030)

Figure 28. Germany Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. France Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. U.K. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Italy Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Russia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Nordic Countries Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Region (2019-2030)

Figure 36. China Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Japan Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. South Korea Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Southeast Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. India Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Australia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Country (2019-2030)

Figure 44. Mexico Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Brazil Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Country (2019-2030)

Figure 48. Turkey Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 49. Saudi Arabia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 50. 3SBio Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 51. 4D Pharma Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 52. Abbvie Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 53. Abzena Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 54. Adaptive Biotechnologies Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 55. Aeglea BioTherapeutics Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 56. Agenus Bio Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 57. Ascension Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 58. Ascentage Pharma Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 59. Aslan Pharma Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 60. Telix Pharmaceuticals Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 61. Basilea Pharmaceutica Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 62. Bavarian Nordic Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 63. Baxalta Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 64. Bayer Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 65. Cantargia Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 66. Apollomics Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 67. Chiome Bioscience Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 68. Clovis Oncology Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 69. Bottom-up and Top-down Approaches for This Report

Figure 70. Data Triangulation

Figure 71. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions